Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement

in Osteoporosis International (2012, March), 23(Suppl. 2), 129-130

An economic evaluation of strontium ranelate for the treatment of male osteoporosis

in Osteoporosis International (2012, March), 23(Suppl. 2), 305-306

Intérêt du Start Back Screening Tool pour proposer une prise en charge adaptée aux patients souffrant de lombalgie

in Actu Kiné (2012)

Quel traitement pour les patients souffrant de lombalgie ?

in Axxon Journal (2012)

A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.

in Statistical Methods in Medical Research (2012)

Clinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms

in Arthritis and Rheumatism (2012), 64(S10), 110

Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study

in Complementary Therapies in Medicine (2012), 20

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at ... [more ▼]

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. Design: Comparative double-blind randomized multicenter study in parallel groups. Setting: 200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS). Intervention: Collagen hydrolysate 1200 mg/day or placebo during 6 months. Main outcome measure: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-totreat procedure. Results: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p < 0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p = 0.53). No significant difference in terms of security and tolerability was observed between the two groups. Conclusions: This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement. [less ▲]

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

in Osteoporosis International (2012), 23

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and ... [more ▼]

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX(R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX(R)-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX(R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate. [less ▲]

Evolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique

in Revue du Rhumatisme (2011, December), 78(Suppl. 5), 43-44